Colorectal Cancer (CRC) Clinical Trials

66 recruitingLast updated: June 17, 2026

There are 66 actively recruiting colorectal cancer (crc) clinical trials across 26 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, San Antonio, Texas, United States, Fairfax, Virginia, United States. Updated daily from ClinicalTrials.gov.


Colorectal Cancer (CRC) Trials at a Glance

66 actively recruiting trials for colorectal cancer (crc) are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 1 with 24 trials, with the heaviest enrollment activity in Houston, San Antonio, and Fairfax. Lead sponsors running colorectal cancer (crc) studies include Revolution Medicines, Inc., The First Affiliated Hospital of Nanchang University, and Gulbenkian Institute for Molecular Medicine.

Browse colorectal cancer (crc) trials by phase

Treatments under study

About Colorectal Cancer (CRC) Clinical Trials

Looking for clinical trials for Colorectal Cancer (CRC)? There are currently 51 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal Cancer (CRC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal Cancer (CRC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 2

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Colorectal Cancer (CRC)
Tao Zhang48 enrolled1 locationNCT07644286
Recruiting
Phase 2

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Colorectal, CancerColon CancerRectal Cancer+1 more
SCRI Development Innovations, LLC60 enrolled14 locationsNCT07011576
Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Colorectal, CancerColon CancerCRC+4 more
Cartography Biosciences80 enrolled8 locationsNCT07321106
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

First-line TreatmentMetastatic Colorectal Cancer (CRC)Phase 1+4 more
M.D. Anderson Cancer Center41 enrolled1 locationNCT07500298
Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Not Applicable

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, ImmunologicalVEGFR-TKI
Federation Francophone de Cancerologie Digestive300 enrolled83 locationsNCT07124858
Recruiting
Phase 1Phase 2

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled21 locationsNCT05379985
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting

CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer

Colorectal Cancer (CRC)Early-onset Colorectal CancerMicrobiome
Gulbenkian Institute for Molecular Medicine400 enrolled2 locationsNCT06734156
Recruiting

Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)

Colorectal Cancer (CRC)Colorectal Cancer ScreeningMicrobiome
Gulbenkian Institute for Molecular Medicine30,000 enrolled1 locationNCT06741293
Recruiting
Phase 2

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Colorectal Cancer (CRC)
Sun Yat-sen University50 enrolled1 locationNCT07448142
Recruiting
Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Summit Therapeutics600 enrolled76 locationsNCT07228832